RNA splicing

SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease

Retrieved on: 
Monday, March 18, 2024
Stem cell, Patient, Ageing, RNA, Longevity, University, Emerging, RNA splicing, Innovate UK, Notifiable disease, Innovation, Vaccine

£3.7 million seed financing supported by consortium of new and existing investors will fund continued preclinical development of therapeutic pipeline programmes.

Key Points: 
  • £3.7 million seed financing supported by consortium of new and existing investors will fund continued preclinical development of therapeutic pipeline programmes.
  • Exeter, UK — 18 March 2024: SENISCA, an award-winning biotechnology company developing RNA-based senotherapeutics to treat age-related disease, today announces it has raised an additional £3.7 million in funding.
  • Dr Sarah Cole, CEO of SENISCA, commented: “This financing round represents another significant milestone for SENISCA.
  • SENISCA has undergone a significant and rapid development and QantX is looking forward to working with the team to realise the full potential of the Company’s disruptive senotherapeutic technology.”

LifeSpan Vision Ventures Invests in SENISCA

Retrieved on: 
Tuesday, March 19, 2024
University, Stem cell, Therapy, RNA splicing, RNA, Longevity, Investment, Notifiable disease, Cell, Science, Vaccine

NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.

Key Points: 
  • NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.
  • Senescent cells behave differently to young, healthy cells in several ways, such as ceasing growth and secreting pro-inflammatory chemicals.
  • Harry Robb, Analyst, LifeSpan Vision Ventures, commented: "We are delighted to join SENISCA as new investors in this financing round.
  • Dr Sarah Cole, CEO of SENISCA, commented: "We are delighted to welcome LifeSpan Vision Ventures to SENISCA.

LifeSpan Vision Ventures Invests in SENISCA

Retrieved on: 
Tuesday, March 19, 2024
University, Stem cell, Therapy, RNA splicing, RNA, Longevity, Investment, Notifiable disease, Cell, Science, Vaccine

NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.

Key Points: 
  • NORWALK, Conn., March 19, 2024 /PRNewswire/ -- LifeSpan Vision Ventures, an investment firm specializing in longevity biotech investments, today announced an investment in SENISCA, an RNA therapeutics spinout from the University of Exeter.
  • Senescent cells behave differently to young, healthy cells in several ways, such as ceasing growth and secreting pro-inflammatory chemicals.
  • Harry Robb, Analyst, LifeSpan Vision Ventures, commented: "We are delighted to join SENISCA as new investors in this financing round.
  • Dr Sarah Cole, CEO of SENISCA, commented: "We are delighted to welcome LifeSpan Vision Ventures to SENISCA.

Why some RNA drugs work better than others

Retrieved on: 
Wednesday, March 6, 2024
Infant, Research, Drug development, Krainer, SMA, RNA, Risdiplam, Genome, Patient, SPRING, Pancreatic cancer, Cold Spring Harbor Laboratory, RNA splicing, CSHL, Vaccine

CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.

Key Points: 
  • CSHL Associate Professor Justin Kinney, Krainer, and postdoc Yuma Ishigami have figured out why some splicing-based drugs tend to work better than others.
  • To better understand how this drug works, the Kinney and Krainer labs analyzed risdiplam's interactions with RNA.
  • "Our new study provides insights into the action and specificity of splice-modifying drugs," Krainer says.
  • "This should facilitate the development of more effective drugs and drug combinations for a variety of diseases."

Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development

Retrieved on: 
Friday, January 5, 2024
RNA, DSM-IV codes, Partnership, Drug discovery, Biotechnology, Dynamics, Research, RNA splicing, Patient, Therapy, Pharmaceutical industry

DURHAM, N.C., Jan. 5, 2024 /PRNewswire/ -- Base4 Biotechnology (formerly known as Nymirum) today announced that it has expanded its license agreement with Servier to strengthen the companies' strategic collaboration to develop RNA-targeted small molecule therapeutics. This agreement leverages Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.

Key Points: 
  • This agreement leverages Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.
  • "At Servier, we are always looking for ways to better help patients with unmet medical needs whether through internal or partnered research projects," said Ross Jeggo, Global Head of Neuroscience and Immuno-Inflammation Therapeutic Area at Servier.
  • Base4's proprietary DART Platform (Dynamic Atomic-Resolution RNA Targeting Platform) provides an end-to-end suite of technologies for ensemble-based drug discovery of RNA-targeting small molecules.
  • "We are happy to see the significant progress made by the Base4 and Servier teams," said Joshua Fairbank, Chief Executive Officer and Co-Founder of Base4.

Servier and Base4 Expand Partnership to Advance Neuroscience Drug Development

Retrieved on: 
Friday, January 5, 2024
RNA, DSM-IV codes, Partnership, Drug discovery, Biotechnology, Dynamics, Research, RNA splicing, Patient, Therapy, Pharmaceutical industry

DURHAM, N.C., Jan. 5, 2024 /PRNewswire/ -- Base4 Biotechnology (formerly known as Nymirum) today announced that it has expanded its license agreement with Servier to strengthen the companies' strategic collaboration to develop RNA-targeted small molecule therapeutics. This agreement leverages Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.

Key Points: 
  • This agreement leverages Base4's pioneering drug discovery platform to identify RNA-modulating small molecules to enable and accelerate Servier's research in neuroscience drug candidates.
  • "At Servier, we are always looking for ways to better help patients with unmet medical needs whether through internal or partnered research projects," said Ross Jeggo, Global Head of Neuroscience and Immuno-Inflammation Therapeutic Area at Servier.
  • Base4's proprietary DART Platform (Dynamic Atomic-Resolution RNA Targeting Platform) provides an end-to-end suite of technologies for ensemble-based drug discovery of RNA-targeting small molecules.
  • "We are happy to see the significant progress made by the Base4 and Servier teams," said Joshua Fairbank, Chief Executive Officer and Co-Founder of Base4.

Fusion Splicer Market Trends 2023: Economic Challenges, Opportunities, and Key Players - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 30, 2023
Technology, Hardware, Pressure, Health, Telecommunications, COVID-19, Software, COVID, Personal Software Services, RNA splicing, Climate change, Investment, Risk, Growth, Food, Pharmaceutical industry, Video game, Arms industry

The report provides a comprehensive analysis of the global Fusion Splicer market, focusing on recent past, current, and future trends.

Key Points: 
  • The report provides a comprehensive analysis of the global Fusion Splicer market, focusing on recent past, current, and future trends.
  • The analysis covers various aspects of the Fusion Splicer market, including hardware, software & services, as well as specific end-use industries such as telecommunications, healthcare, aerospace & defense, automotive, residential, and other applications.
  • This comprehensive overview aims to provide insights into the market's evolution and potential trends in the coming years.
  • The U.S. Market is Estimated at $193.6 Million, While China is Forecast to Grow at 8.2% CAGR
    The Fusion Splicer market in the U.S. is estimated at US$193.6 Million in the year 2022.

New Computational Tool Identifies Novel Targets for Cancer Immunotherapy

Retrieved on: 
Wednesday, May 17, 2023
Antigen, National academy, University, CHOP, IRIS, HLA, Nucleotide, National Cancer Institute, Eli, Survival, Cancer, Research, Child, RNA, Doctor of Philosophy, National Institutes of Health, Cancer Breakthroughs 2020, Proteomics, TCR, Alternative splicing, Genetic distance, Bangladesh Technical Education Board, Regenerative medicine, Stem cell, Cancer Research Institute, Protein, Molecular genetics, Hematological Cancer Research Investment and Education Act, Computation, Patient, Immune system, Peptide, DOI, Growth, Neoplasm, Hospital, UCLA, Protein isoform, RNA splicing, Disease, Children's Hospital of Philadelphia, Vaccine, Microbiology, NEPC, Immunotherapy, MD, Science, Immunology

PHILADELPHIA, May 17, 2023 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) and the University of California, Los Angeles (UCLA) have developed a computational platform capable of discovering tumor antigens derived from alternative RNA splicing, expanding the pool of cancer immunotherapy targets. The tool, called "Isoform peptides from RNA splicing for Immunotherapy target Screening" (IRIS), was described in a paper published today in the Proceedings of the National Academy of Sciences.

Key Points: 
  • "We know that aberrant alternative RNA splicing is widespread in cancer and generates a range of potential immunotherapy targets.
  • In our study, we were able to show that our computational platform was able to identify immunotherapy targets that arise from alternative splicing, introducing a broadly applicable framework for discovering novel cancer immunotherapy targets that arise from this process."
  • "This proof-of-concept study demonstrates that alternatively spliced RNA transcripts are viable targets for cancer immunotherapy and provides a big data and multiomics-powered computational platform for finding these targets," Dr. Xing added.
  • "IRIS: discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing," Proceedings of the National Academy of Sciences, online May 16, 2023, DOI: 10.1073/pnas.2221116120

Geron Presentations at Upcoming EHA Annual Meeting to Report Updated Durability, Disease Modification and Favorable Patient Reported Outcomes (PRO) in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Retrieved on: 
Thursday, May 11, 2023
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Hospitals, Science, Clinical Trials, Neutropenia, Abstract, TET2, DNA, European Hematology Association, TI, Imetelstat, Chromosome, Infection, RNA, VAF, MDS, Corporation, ASXL1, Geron Corporation, Patient, Risk, CEST, Cytopenia, EHA, Public, RS, Transfusion-associated circulatory overload, DNA methylation, Gene, Thrombocytopenia, RNA splicing, Fatigue, Pharmaceutical industry, DNMT3A, SF3B1

The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.

Key Points: 
  • The continuous TI for more than one year represents substantial relief from transfusion-associated complications for this lower risk MDS patient population.
  • As reported in January, 39.8% (47/118) of imetelstat-treated patients versus 15.0% (9/60) of placebo-treated patients achieved the study primary endpoint of 8-week TI (P
  • As noted in the abstract, a main therapeutic goal in lower risk MDS is to alter disease biology by eradicating malignant clones.
  • Of the 178 patients enrolled in IMerge Phase 3, 22.0% of imetelstat-treated patients and 21.7% of placebo-treated patients had baseline cytogenetic abnormalities.

BioMed X and Merck Expand Collaboration Aiming to Leverage Cancer-Specific Vulnerabilities for Targeted Therapies

Retrieved on: 
Tuesday, April 4, 2023
TRON, Neoplasm, Antigen, DDR, Cancer, Biomedical Research, Research, RNA, Messenger, DNA, Patient, BioMed Central, ISCB Senior Scientist Award, Merck, RNA splicing, Vaccine

After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.

Key Points: 
  • After successfully completing a project in RNA splicing in cancer this January, BioMed X and Merck continue their oncology collaboration to explore tumor immunogenicity enhancers.
  • HEIDLEBERG, Germany, Apr 4, 2023 - (ACN Newswire) - BioMed X, an independent biomedical research institute, announces the start of its new research project - "New Strategies to Enhance the Immunogenicity of Tumors" - in collaboration with Merck.
  • asks Dr. Christian Tidona, Founder and Managing Director of the BioMed X Institute.
  • The most recently completed BioMed X project was also a Merck collaboration investigating RNA splicing patterns in cancer.